Aspire-Lakewood Holdings, Inc. (ASBP) stock
Close on Nov 12, 2026Market cap $11.78MP/E –Yield –
Aspire-Lakewood Holdings, Inc. reported revenue of $97.66K for the twelve months to Jun 30, 2026. At the latest close the market valued the company at $11.78M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $11.78M
- P/E ratio
- –
- Price to sales
- 120.64
- Price to book
- 1.00
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $97.66K
- Net income
- -$11.05M
- EPS, diluted
- -$16.38
- Book value per share
- $11.33
- Diluted shares
- 1M
Trading
- Previous close
- $8.80
- Open
- $8.41
- Day's range
- $8.23 – $8.74
- Volume
- 13,890
- Average volume (20 days)
- 24,281
- 52-week range
- $0.11 – $174.74
- RSI (14 days)
- 51.7
- Volatility (1 year)
- 10532.4%
- Relative volume
- 0.40×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ASBP | S&P 500 | Difference | ASBP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.0% | -2.7% | +10.7 pts | ||
| 3 months | +17.8% | -1.7% | +19.6 pts | ||
| Year to date | +59.2% | +11.9% | +47.3 pts | ||
| 1 year | +95.7% | +12.0% | +83.7 pts | ||
| 3 years | -99.9% | +78.2% | −178.1 pts | -91.4% | +21.2% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Aspire-Lakewood filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Update
- Update
About Aspire-Lakewood
Pharmaceutical Preparations
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical firm that develops and commercializes novel sublingual delivery technologies designed for known pharmaceuticals and nutraceuticals. Its proprietary delivery mechanism provides rapid sublingual absorption directly into the bloodstream in soluble powder or granule form, bypassing the gastrointestinal tract to minimize side effects and enhance therapeutic efficacy. The company primarily targets emergency care and acute conditions, initially developing a high-dose sublingual aspirin candidate intended for heart attack and stroke prevention, acute pain relief, and emergency intervention. Its planned customer base includes hospitals, specialty care settings, and medical practitioners treating cardiovascular and pain management patients.
Company profile, executives and historyAspire-Lakewood stock: common questions
What is Aspire-Lakewood's stock price?
ASBP closed at $8.40 on Nov 12, 2026, down 4.55% on the day. Over the past 52 weeks it traded between $0.11 and $174.74.
What is Aspire-Lakewood's market cap?
Aspire-Lakewood was worth $11.78M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ASBP's P/E ratio?
Aspire-Lakewood lost money over fiscal 2025 (diluted EPS -$16.38), so it has no meaningful P/E ratio.
How much revenue does Aspire-Lakewood make?
Aspire-Lakewood reported revenue of $97.66K for the twelve months to Jun 30, 2026.
Does Aspire-Lakewood pay a dividend?
No. Aspire-Lakewood has not paid a cash dividend over the last twelve months.
How has ASBP stock performed over the past year?
Including dividends, ASBP returned +95.7% over the past year, against +12.0% for the S&P 500.
Who are Aspire-Lakewood's competitors?
Companies most similar to Aspire-Lakewood by business, industry and size include IXHL, SILO, LEXX, SNGX, HIND.
See a number that looks wrong?